MX2013001227A - Compuestos y metodos para reparacion de piel. - Google Patents

Compuestos y metodos para reparacion de piel.

Info

Publication number
MX2013001227A
MX2013001227A MX2013001227A MX2013001227A MX2013001227A MX 2013001227 A MX2013001227 A MX 2013001227A MX 2013001227 A MX2013001227 A MX 2013001227A MX 2013001227 A MX2013001227 A MX 2013001227A MX 2013001227 A MX2013001227 A MX 2013001227A
Authority
MX
Mexico
Prior art keywords
methods
compounds
skin repair
skin
treating
Prior art date
Application number
MX2013001227A
Other languages
English (en)
Inventor
Larry A Wheeler
Robert M Burk
Scott M Whitcup
Wha Bin Im
Frederick C Beddingfield
Guang L Jiang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2013001227A publication Critical patent/MX2013001227A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Abstract

La descripción proporciona composiciones y métodos para tratar un defecto de la piel. Las composiciones comprenden una cantidad terapéuticamente eficaz de un compuesto útil para el tratamiento de defectos de la piel tales como heridas, cicatrices y arrugas.
MX2013001227A 2010-07-30 2011-07-29 Compuestos y metodos para reparacion de piel. MX2013001227A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US41911510P 2010-12-02 2010-12-02
PCT/US2011/045833 WO2012016109A2 (en) 2010-07-30 2011-07-29 Compounds and methods for skin repair

Publications (1)

Publication Number Publication Date
MX2013001227A true MX2013001227A (es) 2013-04-24

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001227A MX2013001227A (es) 2010-07-30 2011-07-29 Compuestos y metodos para reparacion de piel.

Country Status (17)

Country Link
US (1) US20120136011A1 (es)
EP (1) EP2598140B1 (es)
JP (1) JP2013536183A (es)
KR (1) KR20130130694A (es)
CN (1) CN103068382A (es)
AR (1) AR082428A1 (es)
AU (1) AU2011282549A1 (es)
BR (1) BR112013002319A2 (es)
CA (1) CA2806982A1 (es)
CL (1) CL2013000308A1 (es)
CO (1) CO6680670A2 (es)
MX (1) MX2013001227A (es)
NZ (1) NZ607306A (es)
RU (1) RU2013108394A (es)
SG (1) SG187653A1 (es)
TW (1) TW201210601A (es)
WO (1) WO2012016109A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
EP2605762A1 (en) * 2010-08-19 2013-06-26 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2014078434A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
CA2890034A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
US9546162B2 (en) * 2013-09-27 2017-01-17 Allergan, Inc. Compounds and methods for skin repair
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
TWI593403B (zh) * 2016-12-01 2017-08-01 yi-ting Xu Remedial repair of facial damage
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (en) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
MXPA04000757A (es) * 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
JP4497320B2 (ja) * 2002-10-10 2010-07-07 小野薬品工業株式会社 内因性修復因子産生促進剤
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
PL209130B1 (pl) * 2003-02-11 2011-07-29 Allergan Inc Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
EA015931B1 (ru) * 2006-12-15 2011-12-30 Глэксо Груп Лимитед Бензамидные производные как агонисты ер-рецепторов
EP2548559A1 (en) * 2006-12-18 2013-01-23 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
AU2008246579A1 (en) * 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Also Published As

Publication number Publication date
KR20130130694A (ko) 2013-12-02
EP2598140B1 (en) 2015-01-14
EP2598140A2 (en) 2013-06-05
US20120136011A1 (en) 2012-05-31
BR112013002319A2 (pt) 2016-05-24
JP2013536183A (ja) 2013-09-19
CN103068382A (zh) 2013-04-24
AU2011282549A1 (en) 2013-02-28
CL2013000308A1 (es) 2013-04-12
WO2012016109A3 (en) 2012-03-22
CO6680670A2 (es) 2013-05-31
SG187653A1 (en) 2013-03-28
CA2806982A1 (en) 2012-02-02
AR082428A1 (es) 2012-12-05
TW201210601A (en) 2012-03-16
NZ607306A (en) 2015-03-27
RU2013108394A (ru) 2014-09-10
WO2012016109A2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MX2013001227A (es) Compuestos y metodos para reparacion de piel.
SG190947A1 (en) Compounds and methods for skin repair
IN2012DN03883A (es)
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2011073279A3 (fr) Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
EP2555760A4 (en) METHODS AND COMPOSITIONS FOR TREATING INJURIES USING CHITOSAN COMPOUNDS
EP2610255A4 (en) NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING THE SAME
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
NZ601350A (en) Method of treating arthritis
HK1223274A1 (zh) 用於治療淺表病變的組合物
EP2531025A4 (en) METHOD FOR TREATING FUNGI FERTIONS, FUNGICIDAL COMPOSITIONS AND THEIR USE
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
MY157341A (en) Methods and compositions for treating lung cancer
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
KR20180085062A (ko) 피부 상태를 치료하기 위한 조성물 및 방법
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
EP3081097B8 (en) Composition for the treatment of infertility
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
EP2624835A4 (en) COMPOSITIONS FOR TREATING SCORIASIS OF SCALP
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
SG178967A1 (en) Antimicrobial compositions and products
MX2011010046A (es) Derivados de diaminopteridina.
MX2012002618A (es) Composiciones para el acabado del cuero que comprenden derivados de dioxolano.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process

Legal Events

Date Code Title Description
FA Abandonment or withdrawal